ReviewViruses2020
Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology.
Review in Viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Sialic acid biophore directed design of enhanced affinity HN protein from Newcastle disease virus.The FEBS journal · 2026Article
- Development and Characterization of a Thermostable Liquid Formulation of Live Newcastle Disease Vaccine.Veterinary sciences · 2026Article
- A recombinant Newcastle disease virus-vectored multi-epitope vaccine confers protection against QX-like infectious bronchitis virus in chickens.Frontiers in immunology · 2026Article
- Assessment of thermostability profile of mesogenic Newcastle disease virus (Genotype XIII) isolates from Assam, India.Veterinary research communications · 2025Article
- Molecular Cloning and Expression of the Fusion (F) Gene from Newcastle Disease virus inArchives of Razi Institute · 2025Article
- Exploring the genetic basis of Newcastle disease virus in chickens: a comprehensive review.Frontiers in immunology · 2025Review
- The heterologous expression of novel recombinant protein composed of HN and F moieties of Newcastle disease virus and immunogenicity evaluation in mouse model.Iranian journal of microbiology · 2024Article
- Oncolytic virotherapy for hepatocellular carcinoma: A potent immunotherapeutic landscape.World journal of gastrointestinal oncology · 2024Article
- Newcastle Disease Vaccination Program in Broilers Using an Apathogenic Heat-Resistant Vaccine.Archives of Razi Institute · 2024Article
- Review
- The effect of 5' and 3' non-translated regions on the expression of a transgene from a Newcastle disease virus vector.Virus research · 2024Article
- Use of live attenuated recombinant Newcastle disease virus carrying avian paramyxovirus 2 HN and F protein genes to enhance immune responses against species A rotavirus VP6 protein.Veterinary research · 2024Article
- Protective effectiveness of two vaccination schemes against the prevalent Egyptian strain of Newcastle disease virus genotype VII.Open veterinary journal · 2024Article
- Negative-Strand RNA Virus-Vectored Vaccines.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Developing a vaccine against velogenic sub-genotype seven of Newcastle disease virus based on virus-like particles.AMB Express · 2023Article
- Immunotherapy: A new target for cancer cure (Review).Oncology reports · 2023Review
- Article
- Towards the future exploration of mucosal mRNA vaccines against emerging viral diseases; lessons from existing next-generation mucosal vaccine strategies.NPJ vaccines · 2022Review
- Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease.Scientific reports · 2022Article
- Viruses as tools in gene therapy, vaccine development, and cancer treatment.Archives of virology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many traditional vaccines have proven to be incapable of controlling newly emerging infectious diseases. They have also achieved limited success in the fight against a variety of human cancers. Thus, innovative vaccine strategies are highly needed to overcome the global burden of these diseases. Advances in molecular biology and reverse genetics have completely restructured the concept of vaccinology, leading to the emergence of state-of-the-art technologies for vaccine design, development and delivery. Among these modern vaccine technologies are the recombinant viral vectored vaccines, which are known for their incredible specificity in antigen delivery as well as the induction of robust immune responses in the vaccinated hosts. Although a number of viruses have been used as vaccine vectors, genetically engineered Newcastle disease virus (NDV) possesses some useful attributes that make it a preferable candidate for vectoring vaccine antigens. Here, we review the molecular biology of NDV and discuss the reverse genetics approaches used to engineer the virus into an efficient vaccine vector. We then discuss the prospects of the engineered virus as an efficient vehicle of vaccines against cancer and several infectious diseases of man and animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.